Moderna is a company that makes special medicine called vaccines to help people not get sick from viruses, like COVID-19. They have made a lot of money and their stock price has gone up a lot because of the good vaccine they made. Some big investors bought a lot of Moderna's stock and options, which are ways to bet on how much the stock will go up or down in the future. We can see what these big investors are doing by looking at their "whale trades". The article also tells us about some other important information like the price and volume of Moderna's stock, and a measurement called RSI that shows if the stock is too expensive or cheap compared to its past performance. Read from source...

- The title is misleading and clickbaity, as it implies that whales are somehow involved in the company or its stock performance. Whales are just a term used to describe large investors who hold significant amounts of shares in a particular company.
- The article lacks clear definitions and explanations of key terms and concepts related to options trading, such as strike price, call volume, put volume, open interest, etc. This makes it difficult for readers who are not familiar with these topics to understand the main points and implications of the analysis.
- The article relies heavily on outdated or irrelevant data, such as the number of mRNA development candidates in clinical trials as of mid-2023, which has no bearing on the current stock price or options activity. It also fails to mention any recent developments or news related to Moderna's business or its COVID-19 vaccine, which could have a significant impact on investor sentiment and expectations.
- The article uses vague and subjective terms to describe the performance of Moderna's stock, such as "present market standing" and "RSI indicators", without providing any concrete data or evidence to support these claims. It also does not compare Moderna's stock performance with that of its peers or the broader market, which would give readers a better perspective on how the company is faring relative to others in the same sector or industry.
- The article ends abruptly and without any clear conclusion or recommendation for investors who are interested in trading options or shares of Moderna. It does not address any potential risks or challenges that could affect the company's future performance, nor does it offer any guidance on how to interpret or use the information presented in the article.